Statistics Collaborative - Design and analysis for biomedical research

PublicationsPublications

Joel Verter

1 | 2 | 3

  • Stoll B, Gordon T, Korones S, Shankaran S, Tyson J, Bauer C, Fanaroff A, Lemons J, Donovan E, Oh W, Stevenson D, Ehrenkranz R, Papile L, Verter J, Wright L. Late–onset sepsis in very low birthweight neonates: The Experience of the NICHD Neonatal Research Network. J Pediatr 1996; 129:63–71.
  • Falletta J, Woods G, Verter J, Buchanan G, Pegelow C, Iyer R, Miller S, Holbrook T, Kinney T, Vichinsky E, Becton D, Wang W, Johnstone H, Wethers D, Reaman G, DeBaun M, Grossman N, Kalinyak K, Jorgensen J, Bjornson A, Thomas M, Reid C. Discontinuing penicillin prophylaxis in children with sickle cell anemia. J Pediatr 1995; 127:685–690.
  • Fanaroff A, Wright L, Stevenson D, Shankaran S, Donovan E, Ehrenkranz R, Younes N, Korones S, Stoll B, Tyson J, Bauer C, Oh W, Lemons J, Papile L, Verter J. Very–low–birthweight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, May 1991 through December 1992. Am J Obstet Gynecol 1995; 173:1423–1431.
  • Wright L, Verter J, Younes N, Stevenson D, Fanaroff A, Shankaran S, Ehrenkranz R, Donovan E. Antenatal corticosteroid administration and neonatal outcome in very low birth weight infants: The NICHD Neonatal Research Network. Am J Obstet Gynecol 1995; 173:269–274.
  • Wright L, Horbar J, Gunkel H, Verter J, Younes N, Andrews E, Long W. Evidence from multicenter networks on the current use and effectiveness of antenatal corticosteroids in low birth weight infants. Am J Obstet Gynecol 1995; 173:263–269.
  • Ben–Menachem T, Fogel R, Patel R, Touchette M, Zarowitz B, Hadzijahic N, Divine G, Verter J, Bersalier R. Prophylaxis for stress–related gastric hemorrhage in the medical intensive care unit. Ann Intern Med 1994; 121:568–575.
  • Stevenson D, Vreman H, Oh W, Fanaroff A, Wright L, Lemons J, Verter J, Shankaran S, Tyson J, Korones S, Bauer C, Stoll B, Papile L, Okah F, Ehrenkranz R. Bilirubin production in well term infants as measured by breath carbon monoxide. Clin Chem 1994; 40:1934–1939.
  • Friedman L, Bristow J, Hallstrom A, Schron E, Proschan M, Verter J, DeMets D, Fisch C, Nies A, Ruskin J, Strauss H, Walters L. Data monitoring in the cardiac arrhythmia suppression trial. Online J Curr Clin Trials 1993;Jul 31 Doc No.79.
  • Johnstone D, Verter J, Limacher M, Rousseau M, Chang-Seng L, Ekelund L, Herman M, Stewart D, Guillote M, Bjerken G, Gaasch W, Held P, Stewart D, Salim Y. Clinical characteristics of patients with severe left ventricular dysfunction: baseline results in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992; 70:894-900.
  • The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685–691.
  • The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992; 327:227–233.
  • The SOLVD Investigators. Effect of enalapril on survival in patient with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:294–302.
  • Hallstrom A, Verter J, Friedman L. Randomizing responders. Control Clin Trials 1991; 12:486–503.
  • Gaston M, Verter J. The sickle cell anemia trial. Stat Med 1990; 9:45–54.
  • Verter J. How much data should we collect in a randomized clinical trial? Stat Med 1990; 9:103–114.
  • The SOLVD Investigators. Studies of left ventricular dysfunction (SOLVD) – rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction. Am J Cardiol 1990; 66:315–322.

1 | 2 | 3